TNFRSF10B and hepatitis B virus infection: In hepatitis B, we have previously proposed the use of TRAIL blockade as an adjunct to therapeutic vaccination because of its potential to prevent NK cell-mediated deletion of TRAIL-R2-bearing antiviral T cells and hepatocytes and thereby favourably shift the balance of immunity and immunopathology39.